Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: Transdermal Estradiol; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 6
States / cities: Freehold, New Jersey • Hamilton, New Jersey • Morristown, New Jersey + 2 more

Conditions: Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Apalutamide, External Beam Radiation Therapy, Placebo Administration; Drug · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 352
States / cities: Gilbert, Arizona • Peoria, Arizona • Scottsdale, Arizona + 251 more

Conditions: Cancer, Solid Tumor
Interventions: CALAA-01; Drug
Lead sponsor: Calando Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • San Antonio, Texas

Conditions: Prostate Adenocarcinoma, Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Angiogram, Catheterization, Gallium Ga-labeled PSMA-11, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Ryan Kohlbrenner, MD; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy; Drug · Other · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more

Conditions: Neoplasms
Interventions: PET tracer (BAY94-9392); Drug
Lead sponsor: Lantheus Biosciences Ltd.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: Ibrutinib, Radical prostatectomy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: San Francisco, California • St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Tinengotinib, abiraterone acetate with prednisone, Enzalutamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: New Haven, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more

Conditions: Prostatic Neoplasms
Interventions: Fluciclovine (18F); Radiation
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Prostate Adenocarcinoma, Prostate Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer, Adenocarcinoma of the Prostate
Interventions: Nivolumab, Degarelix, BMS-986253; Drug
Lead sponsor: Mark Stein; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Philadelphia, Pennsylvania

Conditions: Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
Interventions: 5-Azacitidine, all trans retinoic acid, Lupron; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: myocardial PET imaging; Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 51 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Proscavax; Biological
Lead sponsor: OncBioMune Pharmaceuticals; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Artificial-intelligence (AI); Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostatic Neoplasms, Castration-Resistant
Interventions: Atezolizumab, Enzalutamide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 39
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 33 more

Conditions: Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Tisotumab Vedotin (HuMax-TF-ADC); Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: Orange, California • New Haven, Connecticut • Miami, Florida + 5 more

Conditions: Advanced Solid Tumor
Interventions: XL309, Olaparib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Jacksonville, Florida • Orlando, Florida • Tampa, Florida + 10 more

Conditions: Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: High-Dose Rate Brachytherapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Survey Administration; Radiation · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Low Risk Prostate Cancer
Interventions: assessments; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 3
States / cities: Harrison, New York • New York, New York

Conditions: Metastatic Prostate Cancer
Interventions: [68Ga]PSMA-PET/MRI or PET/CT; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
Interventions: Cabozantinib, Radical Prostatectomy; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: TAS3681; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 11
States / cities: Sacramento, California • Sarasota, Florida • Tampa, Florida + 8 more

Conditions: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: enzalutamide, mifepristone, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 1 more

Search by objective public record fields.

Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

The Use of Artificial Intelligence Generated Contours in Radiation Planning of the Prostate Brachytherapy

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies

PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer